Guangxi Weiwei Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Huluwa Pharmaceutical Group. In November 2015, Huluwa Pharmaceutical Group successfully acquired 64 product approval documents and all sales networks of Nanning Weiwei Pharmaceutical Co., Ltd. and established Guangxi Weiwei Pharmaceutical Co., Ltd.

In order to meet the market needs and better promote the modernization and standardization of traditional Chinese medicine, in 2016, Huluwa Pharmaceutical Group invested 250 million yuan in Nanning National Economic and Technological Development Zone to build the Nanning Production Base Project of the "Huluwa" brand series of medicines, and devoted its efforts to build the Nanning Production Base Project. Become the largest production base for children's Chinese patent medicines in China. The Nanning Production Base Project of the "Culuwa" brand series of medicines covers an area of ​​about 48 mu. It started construction in November 2016, obtained the drug GMP certification in July 2018, and was put into production in August 2018.

In 2020, Huluwa Pharmaceutical Group invested again 330 million yuan to build the second phase of Nanning production base project. The project uses about 41.78 mu of land and construction has started. The second phase of Huluwa Nanning Production Base project is another masterpiece of Huluwa Pharmaceutical Group for implementing the "China Children's Medicine National Brand Strategy", and is of great strategic significance for the group's future development and the expansion of the pharmaceutical industry scale of the Economic and Technological Development Zone. In addition, the group has also built a traditional Chinese medicine extract production base project in Laibin City, which is a supporting project of the Nanning production base.

Guangxi Weiwei Pharmaceutical Co., Ltd. has always adhered to the corporate mission of "Healthy Chinese Babies" and has an intelligent production line, strictly implements the GMP quality assurance system to ensure excellent drug quality. At present, the company has 64 product approval documents, covering all provinces across the country. , municipal and county hospitals, chains, single pharmacies, etc. From the establishment of the factory to the present, Guangxi Weiwei has risen rapidly with a steady development speed and has grown into a benchmark enterprise in Guangxi's pharmaceutical industry. The company is built by Huluwa Pharmaceutical Group The production base of children's Chinese patent medicines carries the production and research and development of key products under the children's medicine brand in the future, laying a solid foundation for Huluwa Pharmaceutical Group to build the first brand of children's medicine in China. In the future, the foundation will be continuously consolidated and added We will strive to achieve high-quality development of enterprises and contribute greater strength to Nanning's economic construction.